1. Home
  2. TTRX

as of 05-13-2026 3:56pm EST

$4.01
+$0.03
+0.75%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Founded: 2015 Country:
United States
United States
Employees: 2 City: WESTLAKE VILLAGE
Market Cap: 107.2M IPO Year: N/A
Target Price: $8.00 AVG Volume (30 days): 19.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.57 - $5.98 Next Earning Date: 05-31-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): -98.72%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: